WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Celebrity birthdays for the week of May 26
Man Utd win FA Cup thriller against Coventry on penalties
China's property sector advances on new fronts
China to improve management of midwife service
The unstoppable duo of Emma Stone and Yorgos Lanthimos
China stay perfect in Thomas & Uber Cup
Messi guides Inter Miami past New England
China's top legislator holds talks with Kazakhstan official
What's next for Iran after death of its president in crash?
China's Ma, Sun crowned at ITTF World Cup
The unstoppable duo of Emma Stone and Yorgos Lanthimos
Senior CPC official meets with guests from Nepal, Germany